Vaccine Therapy and Resiquimod in Treating Patients With Stage II-IV Melanoma That Has Been Removed By Surgery
Status:
Completed
Trial end date:
2017-03-30
Target enrollment:
Participant gender:
Summary
This pilot clinical trial studies vaccine therapy and resiquimod in treating patients with
stage II-IV melanoma that has been removed by surgery. Vaccines made from peptides may help
the body build an effective immune response to kill tumor cell tumor cells. Biological
therapies, such as resiquimod, may stimulate the immune system in different ways and stop
tumor cells from growing. It is not yet known whether Gag:267-274 peptide vaccine and
resiquimod are more effective when given together or separately